Anita Vasudevan

Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.

Palo Alto, Calif. – Cooley represented IDEV Technologies in its $310 million acquisition by Abbott Laboratories. IDEV is a privately-held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. The transaction is expected to close by the end of 2013.

Cooley advised Triphase Accelerator Corporation in its partnership and option-to-acquire arrangement with Celgene to advance a pre-clinical therapeutic developed to treat leukemia and other blood cancers. Under the terms of the agreement, Triphase received an upfront payment of $40 million and, upon exercise of the option, will be eligible to receive up to $940 million in contingent development, regulatory and sales milestones.

Cooley advised BrightFarms on its $100 million Series E financing. Partner Mark Medearis led the Cooley team advising BrightFarms, which is a leading next-generation indoor farming company supplying U.S. grocery retailers with packaged salad greens.